Surgical Therapy and Survival in HCC/ C.F. Zhang et al.

N/ACompletedNCT04820712

Linzhu Zhai664 enrolled

Overview

This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.

The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.

Study Type

OBSERVATIONAL

Enrollment

664

Conditions

Hepatocellular Carcinoma Surgery

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients were diagnosed with colorectal cancer only; 2. Patients with simultaneous metastasis of liver and lung cancer cells; 3. Patients without metastasis resection; 4. whether they underwent palliative primary tumor resection was known; 5. Their cause of death was known; 6. Their survival time were known and greater than 0 month; 7. Patients were diagnosed with microscopic confirmation. Exclusion Criteria: * No

Outcomes

Primary Outcomes

Overall survival

Overall survival was defined as the duration between the surgery and death or the last follow-up

Time frame: 2004.1.1-2013.12.31

Secondary Outcomes

Cancer-specific survival

Cancer-specific survival was defined as the period between the surgery and death due to cancer to reduce the impact of life-threatening comorbidities.